Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Cross

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Neurology|March 25, 2009
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosisR T Naismith, N T Tutlam, J Xu, et al.
Neurology|March 25, 2009
NMO-IgG detected in CSF in seronegative neuromyelitis opticaE C Klawiter, E Alvarez, J Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1987
Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemiasR Goorha, N Bunin, J Mirro, et al.
Neurology|May 26, 2010
Increased diffusivity in acute multiple sclerosis lesions predicts risk of black holeR T Naismith, J Xu, N T Tutlam, et al.
Journal of Neuroimmunology|February 1, 1996
Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthaseW Zhao, R G Tilton, J A Corbett, et al.
Neurology|November 1, 1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placeboL B Krupp, P K Coyle, C Doscher, et al.
The Journal of Clinical Investigation|June 1, 1995
Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulationA H Cross, T J Girard, K S Giacoletto, et al.
Blood|August 1, 1988
Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entityA H Cross, R M Goorha, R Nuss, et al.
Neurology|June 10, 2010
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trialR T Naismith, L Piccio, J A Lyons, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 1999
Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitisJ M Benson, S S Stuckman, K L Cox, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Neurology|March 25, 2009
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosisR T Naismith, N T Tutlam, J Xu, et al.
Neurology|March 25, 2009
NMO-IgG detected in CSF in seronegative neuromyelitis opticaE C Klawiter, E Alvarez, J Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1987
Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemiasR Goorha, N Bunin, J Mirro, et al.
Neurology|May 26, 2010
Increased diffusivity in acute multiple sclerosis lesions predicts risk of black holeR T Naismith, J Xu, N T Tutlam, et al.
Journal of Neuroimmunology|February 1, 1996
Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthaseW Zhao, R G Tilton, J A Corbett, et al.
Neurology|November 1, 1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placeboL B Krupp, P K Coyle, C Doscher, et al.
The Journal of Clinical Investigation|June 1, 1995
Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulationA H Cross, T J Girard, K S Giacoletto, et al.
Blood|August 1, 1988
Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entityA H Cross, R M Goorha, R Nuss, et al.
Neurology|June 10, 2010
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trialR T Naismith, L Piccio, J A Lyons, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 1999
Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitisJ M Benson, S S Stuckman, K L Cox, et al.
Pageof 8